Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

The role of intestinal immunity on obesity-related insulin resistance

FY 2013-14

Summary
Type 2 diabetes and obesity are growing global health concerns. Currently, it is uncertain of how obesity can lead to type 2 diabetes, but obesity predisposes to a state of insulin resistance, which contributes to the disease. Insulin resistance occurs when our body no longer responds to insulin, a hormone secreted by our pancreas, to uptake glucose from the blood predominantly after a meal. Recent research has discovered a link between the immune system and insulin resistance. Normal mice on a high fat diet become obese and develop a metabolic syndrome and insulin resistance similar to type 2 diabetes in humans. Fat tissues in these obese mice have an increased number of white blood cells, including T cells, B cells and macrophages that produce inflammation. When this inflammation is removed, the prognosis of the metabolic disease is improved. Thus, diabetes as a result of high fat diet is partly due to inflammation or an abnormal immune response in body fat. Our studies have shown the development of type 2 diabetes to be highly similar to autoimmune diseases. In addition to inflammation in fatty tissues, our preliminary data has shown that high fat diet also induces inflammation in the small and large intestines and may be the root of fat inflammation seen in diabetes. We propose that bowel inflammation alters the permeability of the gut wall by allowing these inflammatory immune cells to leak through the gut and into fat directly or by sending pro-inflammatory signals to fat immune cells to worsen inflammation. This theory would hugely impact the future treatment of diabetes, as common anti-inflammatory drugs used for inflammatory bowel diseases, such as Crohn’s disease, may also be effective for diabetes. This research proposal aims to define the role of the gut immune system, specifically during inflammation, in the development of type 2 diabetes. Our first objective is to analyze the effect of high fat diet on the cells of the bowel wall in mice to determine if these cells are more leaky and/or inflamed. Our next step is to characterize the different immune cells from the bowels extracted from mice and humans in order to see if there are increases in inflammatory cell types and how their functions contribute to disease. Lastly, we will test the effect of bowel-specific anti-inflammatory drugs, like mesalamine, on treating diabetes. Mesalamine is a commonly prescribed drug for Crohn’s disease, with minimal side effects. Thus, this already-approved drug may also benefit individuals with diabetes. Our research will shed new light on the understanding of diabetes from the viewpoint of the gut immune system and suggest novel treatment options against this disease.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
311826
Name
Luck Helen
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
The role of intestinal immunity on obesity-related insulin resistance
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Adaptive Immune System; Diet; Innate Immune System; Insulin Resistance; Intestinal Immunity; Mesalamine; Metabolic Syndrome; Nutrition; Obesity; Type 2 Diabetes
Abstract
Type 2 diabetes and obesity are growing global health concerns. Currently, it is uncertain of how obesity can lead to type 2 diabetes, but obesity predisposes to a state of insulin resistance, which contributes to the disease. Insulin resistance occurs when our body no longer responds to insulin, a hormone secreted by our pancreas, to uptake glucose from the blood predominantly after a meal. Recent research has discovered a link between the immune system and insulin resistance. Normal mice on a high fat diet become obese and develop a metabolic syndrome and insulin resistance similar to type 2 diabetes in humans. Fat tissues in these obese mice have an increased number of white blood cells, including T cells, B cells and macrophages that produce inflammation. When this inflammation is removed, the prognosis of the metabolic disease is improved. Thus, diabetes as a result of high fat diet is partly due to inflammation or an abnormal immune response in body fat. Our studies have shown the development of type 2 diabetes to be highly similar to autoimmune diseases. In addition to inflammation in fatty tissues, our preliminary data has shown that high fat diet also induces inflammation in the small and large intestines and may be the root of fat inflammation seen in diabetes. We propose that bowel inflammation alters the permeability of the gut wall by allowing these inflammatory immune cells to leak through the gut and into fat directly or by sending pro-inflammatory signals to fat immune cells to worsen inflammation. This theory would hugely impact the future treatment of diabetes, as common anti-inflammatory drugs used for inflammatory bowel diseases, such as Crohn’s disease, may also be effective for diabetes. This research proposal aims to define the role of the gut immune system, specifically during inflammation, in the development of type 2 diabetes. Our first objective is to analyze the effect of high fat diet on the cells of the bowel wall in mice to determine if these cells are more leaky and/or inflamed. Our next step is to characterize the different immune cells from the bowels extracted from mice and humans in order to see if there are increases in inflammatory cell types and how their functions contribute to disease. Lastly, we will test the effect of bowel-specific anti-inflammatory drugs, like mesalamine, on treating diabetes. Mesalamine is a commonly prescribed drug for Crohn’s disease, with minimal side effects. Thus, this already-approved drug may also benefit individuals with diabetes. Our research will shed new light on the understanding of diabetes from the viewpoint of the gut immune system and suggest novel treatment options against this disease.
Competitiondate
201312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Luck, Helen
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~